1. Home
  2. HYI vs TTRX Comparison

HYI vs TTRX Comparison

Compare HYI & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset High Yield Defined Opportunity Fund Inc.

HYI

Western Asset High Yield Defined Opportunity Fund Inc.

HOLD

Current Price

$10.78

Market Cap

136.2M

Sector

Finance

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.35

Market Cap

116.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYI
TTRX
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.2M
116.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HYI
TTRX
Price
$10.78
$3.35
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
68.2K
20.8K
Earning Date
01-01-0001
03-31-2026
Dividend Yield
9.59%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.44
$2.57
52 Week High
$12.12
$5.98

Technical Indicators

Market Signals
Indicator
HYI
TTRX
Relative Strength Index (RSI) 48.56 51.33
Support Level $10.44 $2.98
Resistance Level $11.21 $3.73
Average True Range (ATR) 0.13 0.24
MACD 0.03 0.03
Stochastic Oscillator 64.15 77.40

Price Performance

Historical Comparison
HYI
TTRX

About HYI Western Asset High Yield Defined Opportunity Fund Inc.

Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

Share on Social Networks: